Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of vasopressin (MW ~1069.2 g/mol) with enhanced V2 receptor selectivity and resistance to enzymatic degradation. It is FDA-approved for central diabetes insipidus, hemophilia A (with factor VIII levels >5%), type 1 von Willebrand disease, and primary nocturnal enuresis. Desmopressin is available as injectable, intranasal, oral tablet, and sublingual formulations, making it one of the most versatile peptide medications in clinical use.
Category: Reproductive / Hormonal. Evidence rating: A (strong human clinical data).
Clinical status: FDA-approved (DDAVP for central diabetes insipidus, hemophilia A, type 1 von Willebrand disease, primary nocturnal enuresis)
Desmopressin is a modified vasopressin molecule with two key changes: deamination of the N-terminal cysteine and substitution of L-arginine with D-arginine at position 8. These modifications confer approximately 3000-fold greater antidiuretic (V2) to vasopressor (V1a) activity ratio compared to…
Safety considerations: Hyponatremia and water intoxication: most serious adverse effect, particularly in children and elderly; can cause seizures if severe; Headache (2-5% oral; more common with intranasal); Nausea and abdominal cramps.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-08-12.
Related peptides: Kisspeptin, Gonadorelin, Oxytocin.
Compare: Desmopressin vs Kisspeptin, Desmopressin vs Gonadorelin, Desmopressin vs Oxytocin.
Desmopressin has two chemical modifications that make it much more selective for V2 (antidiuretic) receptors over V1a (vasopressor) receptors, with a ratio approximately 3000 times greater than native vasopressin. It also has a much longer half-life (2-4 hours vs 10-35 minutes) and is resistant to enzymatic degradation, allowing oral, sublingual, and intranasal administration.
The most serious risk is hyponatremia (low sodium) due to excessive water retention, which can cause seizures. This risk is mitigated by restricting fluid intake, monitoring serum sodium especially at treatment initiation, and avoiding use in patients with conditions predisposing to water imbalance.
Yes, desmopressin reduces wet nights by approximately 1-2 per week compared to placebo. However, the effect is often not sustained after discontinuation, with high relapse rates. It is considered a first-line pharmacological treatment for nocturnal enuresis when behavioral interventions alone are insufficient.
Desmopressin stimulates release of von Willebrand factor and factor VIII from vascular endothelial cell storage granules (Weibel-Palade bodies), typically raising factor VIII levels 2-5 fold above baseline within 30-60 minutes. It is effective for mild hemophilia A and type 1 von Willebrand disease but not for severe hemophilia or type 2B/3 VWD.